TLS data
 

BioCommunique

Corporate Newsletter

 
 
Ferring accesses Evotec's integrated small molecule discovery and development platform to progress new molecules from concept to potential drug candidates.

Evotec and Ferring Form Strategic Research Alliance in Reproductive Medicine and Women's Health

  • Fri Nov 09 20:28:00 GMT 2018
  • San Diego
  • Author Evotec and Ferring

Evotec AG and Ferring Pharmaceuticals (“Ferring”) announced a strategic research alliance to discover and develop new small molecule therapies to treat patients living with fertility and gynaecological conditions.

Evotec will apply its drug discovery platform to design novel, safe and efficacious treatments in partnership with Ferring. The multi-target, multi-year collaboration aims to deliver small molecule pre-clinical development (“PDC”) and investigational new drug (“IND”) ready candidates. As part of the alliance, Evotec is eligible for undisclosed research funding and milestones.

Dr Mario Polywka, Chief Operating Officer of Evotec, commented: “The integration of our industry-leading small molecule discovery and development platform with Ferring’s deep disease expertise in reproductive medicine and women’s health will create a powerful combination that we hope will create a difference for patients suffering from infertility and gynaecological disorders. We very much look forward to working with such an innovative partner.”

Per Falk, Chief Science Officer, Ferring, added: “To achieve leadership in reproductive medicine and women’s health, we are expanding beyond our historical expertise in peptides and tackling molecular targets that are best addressed using small molecule therapeutics. Evotec is a highly regarded company in this field, and this alliance offers the prospect of significant innovation for patients. Together, we have the potential to make a difference for both men and women who are struggling to start a family, and for women suffering from gynaecological conditions.”

 
 

Stay in the know with the Biocommunique

Sign up for Biocom's bi-weekly newsletter to get all the latest life science news sent directly to your inbox.

 
 

Related Articles View All

https://www.biocom.org/servlet/servlet.ImageServer?id=0155A00000A2anWQAR&oid=00DA0000000Kz7JMAS  
Apply now for UC San Diego's new program which gives fellows experiences in sharing the university's health science news with the public.
https://www.biocom.org/servlet/servlet.ImageServer?id=0155A00000A2an2QAB&oid=00DA0000000Kz7JMAS  
Hear from Eric Topol, MD and Abraham Verghese, MD on latest trends in AI in medicine, rare disease, oncology and more.
https://www.biocom.org/servlet/servlet.ImageServer?id=0155A00000A2KtKQAV&oid=00DA0000000Kz7JMAS  
Genentech, a subsidiary of Roche, took a dive into the $20 billion NASH market with the acquisition of San Diego-based Biocom member, Jecure Therapeutics, a company with a portfolio of preclinical NLRP3 inhibitors aimed at serious inflammatory diseases.
https://www.biocom.org/servlet/servlet.ImageServer?id=0155A00000A2EyZQAV&oid=00DA0000000Kz7JMAS  
Take in important insights from Intuitive Surgical CEO Gary Guthart, Reva Medical CEO Reggie Groves and the executive chairman of the Alfred E. Mann Foundation, Dr. Robert Greenberg.